Kalaris Therapeutics, Inc. (KLRS) — Stock Score Summary

Kalaris Therapeutics, Inc. (KLRS) has a MoatMap StockRank of 4/100 based on Quality (29/100), Value (32/100), and Momentum (18/100) factor scores. The current signal is STRONG SELL. Small-cap biotech company with a high-risk, binary outcome profile inherent to drug development. No direct or asymmetric tailwind from the identified macro themes, nor does it fit the quality compounder criteria without a proven commercial product and established moat.

Kalaris Therapeutics, Inc. is an early-stage biotechnology company focused on discovering and developing novel therapeutic candidates for unmet medical needs. Its competitive position relies on proprietary intellectual property surrounding its drug candidates and scientific expertise in specific disease pathways. As a preclinical-stage firm, Kalaris Therapeutics represents a speculative healthcare venture, where valuation is driven by pipeline potential and scientific breakthroughs rather than current revenue.

Key Financial Metrics

Price$5.18
Market Cap$117M
P/E (Forward)-3.30
Price/Book1.51
Return on Equity-66.6%
Return on Invested Capital-37.5%
Gross Margin0.0%
Operating Margin0.0%

Kalaris Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Kalaris Therapeutics, Inc.’s (KLRS) StockRank?
MoatMap’s StockRank for Kalaris Therapeutics, Inc. (KLRS) is 4/100, with a Strong Sell signal. It is a composite of Quality (29), Value (32), and Momentum (18) factor ranks across MoatMap’s 19,000+ stock universe.
Does Kalaris Therapeutics, Inc. have an economic moat?
Kalaris Therapeutics, Inc. (KLRS) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Kalaris Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Kalaris Therapeutics, Inc. (KLRS) is Strong Sell, based on a StockRank of 4/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Kalaris Therapeutics, Inc. in?
Kalaris Therapeutics, Inc. (KLRS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksKLRS deep dive reportAI ChampionsHow we score stocksSense-check another stock